Related references
Note: Only part of the references are listed.Nusinersen for SMA: expanded access programme
Michelle A. Farrar et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Transforaminal lumbar puncture for intrathecal nusinersen administration
Anthony P. Geraci et al.
MUSCLE & NERVE (2018)
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen for Spinal Muscular Atrophy Are We Paying Too Much for Too Little?
Vinay Prasad
JAMA PEDIATRICS (2018)
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 A cohort study
Karolina Aragon-Gawinska et al.
NEUROLOGY (2018)
Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
Aurelie Chabanon et al.
PLOS ONE (2018)
Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study
E. Bertini et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2017)
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Enrico Bertini et al.
LANCET NEUROLOGY (2017)
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience
Sonia Messina et al.
NEUROMUSCULAR DISORDERS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review
Ingrid E. C. Verhaart et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Newborn screening for spinal muscular atrophy: The views of affected families and adults
Felicity K. Boardman et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2017)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Disease burden of spinal muscular atrophy in Germany
Constanze Klug et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy
Michelle A. Farrar et al.
JOURNAL OF PEDIATRICS (2013)
Spinal muscular atrophy: going beyond the motor neuron
Gillian Hamilton et al.
TRENDS IN MOLECULAR MEDICINE (2013)
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
Paul N. Porensky et al.
HUMAN MOLECULAR GENETICS (2012)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron
NK Singh et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN
CL Lorson et al.
HUMAN MOLECULAR GENETICS (2000)
Share Paper
